# Michael McGarrity

Type: Person

Source: GetYourBrief — https://getyourbrief.com/entity/michael-mcgarrity
Canonical HTML page: https://getyourbrief.com/entity/michael-mcgarrity

## Timeline

- **2026**: NDA Submission — Planned submission of paltusotine New Drug Application to the FDA.
- **2026**: Phase 3 Initiation — Anticipated start of Phase 3 trials for atumelnant in CAH and Cushing's disease.
- **2025-Q4**: Earnings Call — Management confirms commercial readiness and pipeline acceleration.
- **2025-Q3**: PATHFNDR-2 Success — Completion of Phase 3 trial for paltusotine in acromegaly with positive results.

## Recent coverage (3 stories, network-wide)

### Crinetics (CRNX) Advances Toward Commercialization Amid Q4 2025 Earnings Wave
2026-02-27 01:35:34 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Crinetics Pharmaceuticals (CRNX) reported Q4 2025 results, highlighting critical progress in its endocrine pipeline and preparations for the commercial launch of paltusotine. Alongside results from MDxHealth and Baldwin, the earnings cluster reflects a strategic transition for mid-cap healthcare and service firms navigating the 2026 market landscape.
Full story: https://getfinancebrief.com/story/crinetics-crnx-q4-2025-earnings-analysis

### Crinetics Signals Commercial Readiness as Lead Candidates Near FDA Submission
2026-02-27 01:34:00 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 3

Crinetics Pharmaceuticals reported strong Q4 2025 results, highlighting the successful completion of Phase 3 trials for paltusotine and preparations for a 2026 New Drug Application (NDA). The company is positioning itself for a major commercial pivot in endocrine disorders, supported by a robust balance sheet and positive data for its second lead candidate, atumelnant.
Full story: https://getbiobrief.com/story/crinetics-crnx-q4-2025-earnings-pipeline-analysis

### Q4 2025 Earnings: Precision Diagnostics and Endocrine Innovation Drive Growth
2026-02-27 01:33:26 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 3

The Q4 2025 earnings reports from Crinetics, MDxHealth, and Baldwin highlight a pivotal shift toward precision diagnostics and specialized endocrine therapies. These results underscore a robust recovery in diagnostic volumes and a maturing pipeline for rare disease treatments entering commercialization phases.
Full story: https://gethealthbrief.com/story/q4-2025-healthcare-earnings-crinetics-mdxhealth-baldwin

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.